This investigation or therapeutic intervention is of very clear disadvantage for people and will be averted or omitted in any scenariog., PARP inhibitor) to be a consequence of knowledge on the use of PARP inhibitors in BRCA1/two mutation carriers with Highly developed breast most cancers (LoE 1b/GR B/AGO+) [6] (see also the chapter on treatment of